About this trial
Contrast-Enhanced Mammography (CEM) is a functional breast imaging technology. Like magnetic resonance imaging (MRI), CEM neovascularization enhancement can improve cancer detection rates, while lack of enhancement may lead to benign determination. The advantages of CEM are dramatically apparent in women with dense breasts. The purpose of this study was to investigate the additional diagnostic value of CEM added to the standard practice of mammography plus ultrasonography(US) in patients with suspicious breast lesions.
This study was a single-center prospective-retrospective combined observational study. In the prospective part, women with suspected breast abnormalities undergo prospective CEM evaluation, including acquisition of low energy (LE) images and recombined images (RI) showing enhancement, concurrently with breast US. The retrospective part selected the mammography and breast US data of female patients with suspected breast abnormalities who had previous baseline matching.
Eligibility criteria
Qualifiers
Breast ultrasound or/and general mammography suggest that the lesion is BI-RADS 4 or above;
Willing to undergo enhanced mammography examination;
Agree to perform tumor core needle biopsy or excisional biopsy to confirm pathological diagnosis when necessary.
Disqualifiers
Allergy to iodinated contrast;
Pregnant and lactating women;
Suffering from kidney disease or abnormal kidney function, or undergoing renal dialysis;
The breast is too large to be completely included in the full-field mammography examination at one time; ○5 Those with breast implants.
Trial design
Treatments tested in this trial
- Contrast-Enhanced Mammography
Treatment groups
Sponsors and collaborators
ZHOU Yidong
Lead sponsor
Peking Union Medical College Hospital
Sponsor institution